Adoption of self‐measured blood pressure monitoring in underserved communities: Program evaluation in primary care
Journal of Evaluation in Clinical Practice · 2025
DOI: 10.1111/jep.14130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Evaluation in Clinical Practice, 2025. Verfasst von Maureen Shields und 5 weiteren Autor:innen. Beteiligte Einrichtung: Advocate Aurora Research Institute, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Primary Health Care, Hypertension, Blood Pressure Monitoring, Ambulatory, Medically Underserved Area. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Rationale
Self‐measured blood pressure (SMBP) monitoring is crucial for hypertension management, yet its adoption, particularly among disadvantaged populations, remains low. ‘Love Your Heart’ is a quality improvement program providing free standard SMBP devices to hypertensive patients, aiming to enhance adoption and assess its impact on blood pressure control. Aims and Objectives This study evaluates the ‘Love Your Heart’ program's implementation success through assessing adoption rates and exploring changes in systolic blood pressure (SBP) among participants. We aim to understand factors influencing adoption and potential benefits of SMBP monitoring in a diverse, socially disadvantaged patient population.
Methods
We retrospectively evaluated the ‘Love Your Heart’ program using electronic health records (EHR) at a primary care site in Chicago. Adult patients with hypertension were enroled in the 6‐month program, which included education sessions and free SMBP devices. Adoption was measured by participation in program components, and changes in SBP were analysed based on adoption status. Statistical analyses were conducted using SAS software, adhering to STROBE reporting guidelines.
Results
Of 621 eligible patients, 104 participated, with 83 included in the evaluation. Despite all participants receiving free SMBP devices, adoption rates were modest, with only 7% sharing readings with the care team. However, patients who received device instructions demonstrated greater decreases in SBP compared to those who did not. Although not statistically significant, clinically meaningful decreases in SBP were observed among adopters.
Conclusion
The ‘Love Your Heart’ program highlights the challenges of promoting SMBP monitoring among disadvantaged patient populations. While providing free devices addresses access barriers, low reporting to the care team suggests the need for further support mechanisms. Future research should explore strategies to enhance SMBP adoption and integration into clinical care, particularly in settings lacking automated data transmission systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Advocate Aurora Research Institute, Milwaukee, Wisconsin, USA.
- Advocate Health, Milwaukee, Wisconsin, USA.
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
ORCID-Profile: Maureen Shields
Zitieren
APA
Shields, M., Guzman, I., Rouse, J., Siddiqi, A., Pletcher, M. J., & Khatib, R. (2025). Adoption of self‐measured blood pressure monitoring in underserved communities: Program evaluation in primary care. Journal of Evaluation in Clinical Practice. https://doi.org/10.1111/jep.14130
Vancouver
Shields M, Guzman I, Rouse J, Siddiqi A, Pletcher MJ, Khatib R. Adoption of self‐measured blood pressure monitoring in underserved communities: Program evaluation in primary care. Journal of Evaluation in Clinical Practice. 2025. doi:10.1111/jep.14130
BibTeX
@article{Shields2025,
author = {Shields, Maureen and Guzman, Iridian and Rouse, Jackie and Siddiqi, Alvia and Pletcher, Mark J and Khatib, Rasha},
title = {Adoption of self‐measured blood pressure monitoring in underserved communities: Program evaluation in primary care},
journal = {Journal of Evaluation in Clinical Practice},
year = {2025},
doi = {10.1111/jep.14130}
}
EUVIMED